Assembly Biosciences starts phase 2 trial of HDV treatment
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $ASMB +1.56% in the latest session.
- Timing: Filed after the close: the price beside it finished its day before the story existed, so the next session gets the first real vote.
Where the stock stands
$ASMB last traded at $20.89, +1.56% on the session. That puts it 47% shy of its 52-week high of $39.71 and 8.2% clear of its low of $19.30 — within a tenth of its 52-week low. Over the year it has ranged 106% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $ASMB page.
How much coverage it is getting
Nothing else on $ASMB in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$ASMB earnings in 11 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $ASMB page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ASMB is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ASMB. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.